SEC Info - Acadia Pharmaceuticals Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

Acadia Pharmaceuticals Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.SCH’

On: Tuesday, 2/27/24, at 6:01pm ET · As of: 2/28/24 · For: 12/31/23 · Accession #: 950170-24-21473 · File #: 0-50768

Previous ‘10-K’: ‘10-K’ on 2/28/23 for 12/31/22 · Latest ‘10-K’: This Filing · 24 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Acadia Pharmaceuticals Inc.       10-K       12/31/23   88:14M                                    Donnelley … Solutions/FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.81M 
 3: EX-10.13    Material Contract                                   HTML     40K 
 4: EX-10.17    Material Contract                                   HTML    610K 
 5: EX-10.18    Material Contract                                   HTML     32K 
 6: EX-10.19    Material Contract                                   HTML     31K 
 7: EX-10.20    Material Contract                                   HTML     44K 
 8: EX-10.35    Material Contract                                   HTML    355K 
 9: EX-10.36    Material Contract                                   HTML    289K 
10: EX-10.37    Material Contract                                   HTML     63K 
11: EX-10.38    Material Contract                                   HTML    366K 
 2: EX-10.5     Material Contract                                   HTML     97K 
12: EX-21.1     Subsidiaries List                                   HTML     26K 
13: EX-23.1     Consent of Expert or Counsel                        HTML     28K 
18: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     39K 
                Awarded Compensation                                             
14: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
15: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
16: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
17: EX-32.2     Certification -- §906 - SOA'02                      HTML     27K 
20: R1          Document and Entity Information                     HTML     99K 
21: R2          Consolidated Balance Sheets                         HTML    126K 
22: R3          Consolidated Balance Sheets (Parenthetical)         HTML     45K 
23: R4          Consolidated Statements of Operations               HTML     94K 
24: R5          Consolidated Statements of Comprehensive Loss       HTML     48K 
25: R6          Consolidated Statements of Cash Flows               HTML    120K 
26: R7          Consolidated Statements of Stockholders' Equity     HTML     77K 
27: R8          Pay vs Performance Disclosure                       HTML     38K 
28: R9          Insider Trading Arrangements                        HTML     46K 
29: R10         Organization and Business                           HTML     29K 
30: R11         Summary of Significant Accounting Policies          HTML    185K 
31: R12         Investments                                         HTML    151K 
32: R13         Fair Value Measurements                             HTML    132K 
33: R14         Balance Sheet Details                               HTML     91K 
34: R15         Stockholders' Equity                                HTML    124K 
35: R16         401(k) Plan                                         HTML     33K 
36: R17         Income Taxes                                        HTML    199K 
37: R18         Commitments and Contingencies                       HTML     64K 
38: R19         Leases                                              HTML     92K 
39: R20         Selected Quarterly Financial Data (Unaudited)       HTML     89K 
40: R21         SCHEDULE II - Valuation and Qualifying Accounts     HTML     54K 
41: R22         Summary of Significant Accounting Policies          HTML    239K 
                (Policies)                                                       
42: R23         Summary of Significant Accounting Policies          HTML    131K 
                (Tables)                                                         
43: R24         Investments (Tables)                                HTML    148K 
44: R25         Fair Value Measurements (Tables)                    HTML    130K 
45: R26         Balance Sheet Details (Tables)                      HTML     93K 
46: R27         Stockholders' Equity (Tables)                       HTML     81K 
47: R28         Income Taxes (Tables)                               HTML    193K 
48: R29         Leases (Tables)                                     HTML     84K 
49: R30         Selected Quarterly Financial Data (Unaudited)       HTML     88K 
                (Tables)                                                         
50: R31         Summary of Significant Accounting Policies -        HTML     35K 
                Schedule of Reconciliation of Cash, Cash                         
                Equivalents and Restricted Cash (Detail)                         
51: R32         Summary of Significant Accounting Policies -        HTML     76K 
                Additional Information (Detail)                                  
52: R33         Summary of Significant Accounting Policies -        HTML     36K 
                Schedule of Estimated Useful Lives by Major Asset                
                Category (Detail)                                                
53: R34         Summary of Significant Accounting Policies -        HTML     37K 
                Schedule of Revenues consist of product sales to                 
                customers (Details)                                              
54: R35         Summary of Significant Accounting Policies -        HTML     36K 
                Weighted-Average Assumptions Used to Estimate Fair               
                Value of Employee Stock Options (Detail)                         
55: R36         Summary of Significant Accounting Policies -        HTML     44K 
                Weighted-Average Assumptions Used to Estimate Fair               
                Value of Employee Stock Purchase Plan Rights                     
                (Detail)                                                         
56: R37         Summary of Significant Accounting Policies -        HTML     35K 
                Summary of Stock-based Compensation Expense                      
                Included in Statements of Operations (Detail)                    
57: R38         Investments - Carrying Value and Amortized Cost of  HTML     58K 
                Company's Investments Summarized by Major Security               
                Type (Detail)                                                    
58: R39         Investments - Additional Information (Detail)       HTML     35K 
59: R40         Investments - Summary of Gross Unrealized Losses    HTML     53K 
                and Fair Value of Available-For-Sale Investment                  
                Securities in Unrealized Loss Position (Detail)                  
60: R41         Fair Value Measurements - Fair Value Measurements   HTML     62K 
                of Cash Equivalents, Available-For-Sale Investment               
                Securities and Equity Securities (Detail)                        
61: R42         Fair value measurement - Changes in estimated fair  HTML     34K 
                value of contingent cash award (Details)                         
62: R43         Balance Sheet Details - Schedule of Inventory       HTML     38K 
                (Detail)                                                         
63: R44         Balance Sheet Details - Property and Equipment,     HTML     40K 
                Net (Detail)                                                     
64: R45         Balance Sheet Details - Additional Information      HTML     29K 
                (Detail)                                                         
65: R46         Balance Sheet Details - Schedule of Accrued         HTML     42K 
                Liabilities (Detail)                                             
66: R47         Stockholders' Equity - Additional Information       HTML    141K 
                (Detail)                                                         
67: R48         Summary of Company's Stock Option Activity          HTML     68K 
                (Detail)                                                         
68: R49         Summary of Company's RSU Activity (Detail)          HTML     51K 
69: R50         401 (k) Plan - Additional Information (Detail)      HTML     33K 
70: R51         Income Taxes - Summary of Domestic and Foreign      HTML     34K 
                Pre-tax Loss (Detail)                                            
71: R52         Income Taxes - Schedule of Income Tax Provision     HTML     40K 
                (Details)                                                        
72: R53         Income Taxes - Additional Information (Detail)      HTML     62K 
73: R54         Income Taxes - Components of Deferred Tax Assets    HTML     61K 
                (Detail)                                                         
74: R55         Income Taxes - Reconciliation of Income Taxes to    HTML     60K 
                Amount Computed by Applying Statutory Federal                    
                Income Tax Rate to Pretax Loss (Detail)                          
75: R56         Income Taxes - Unrecognized Tax Benefits (Detail)   HTML     34K 
76: R57         Commitments and Contingencies - Additional          HTML     95K 
                Information (Detail)                                             
77: R58         Leases - Additional Information (Detail)            HTML     88K 
78: R59         Leases - Summary of Operating Lease Costs (Detail)  HTML     31K 
79: R60         Leases - Supplemental Cash Flow Information         HTML     29K 
                Related to the Company's Leases (Detail)                         
80: R61         Leases - Summary of Balance Sheet Classification    HTML     33K 
                of Lease Liabilities (Detail)                                    
81: R62         Leases - Summary of Maturities of Lease             HTML     46K 
                Liabilities (Detail)                                             
82: R63         Selected Quarterly Financial Data (Unaudited) -     HTML     72K 
                Selected Quarterly Financial Data (Detail)                       
83: R64         SCHEDULE II - Valuation and Qualifying Accounts     HTML     37K 
                (Detail)                                                         
85: XML         IDEA XML File -- Filing Summary                      XML    147K 
88: XML         XBRL Instance -- acad-20231231_htm                   XML   2.93M 
84: EXCEL       IDEA Workbook of Financial Report Info              XLSX    167K 
19: EX-101.SCH  XBRL Taxonomy Extension Schema With Embedded         XSD   3.61M 
                Linkbases Document -- acad-20231231                              
86: JSON        XBRL Instance as JSON Data -- MetaLinks              566±   903K 
87: ZIP         XBRL Zipped Folder -- 0000950170-24-021473-xbrl      Zip    988K

‘EX-101.SCH’ — XBRL Taxonomy Extension Schema With Embedded Linkbases Document — acad-20231231

This Exhibit is an XBRL File.

<?xml version="1.0" encoding="windows-1252"?>

<xsd:schema targetNamespace="http://www.acadia-pharm.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20231231" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">

<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>

<xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>

<xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>

<xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>

<xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>

<xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>

<xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>

<xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>

<xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>

<xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>

<xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>

<xsd:annotation>

<xsd:appinfo>

<link:roleType roleURI="http://www.acadia-pharm.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">

<link:definition> 100000 - Document - Document and Entity Information </link:definition>